Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Glioblastoma 1Breast Neoplasms 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

lutetium Lu 177 dotatate 20Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4amino-acid, glucose, and electrolyte solution 4Capecitabine 4olaparib 3lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Interleukin-13 × 1 year × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡